Nexalis Therapeutics Limited has released a press release.
First patient dosed in IRX-616a Phase 1 trial
Earlier from Nexalis Therapeutics
- First eligible participant screened - phase 1 IRX-616a study
- Preliminary Final Report
- Dec25 Quarterly Activities Report
- Dec25 Appendix 4C Cash Flow Report